Speakers:

• Kenneth (Ken) Bradley, Global Head, Infectious Disease Discovery, Roche (Switzerland)
• Diarmaid Hughes, Professor of Medical Molecular Bacteriology, Uppsala University (Sweden)

Moderator:

• Karen Bush, Professor of Practice in Biotechnology, Emerita, Indiana University (USA)

Presentation 1: Progression criteria and Go/NoGo decisions in antibacterial drug discovery – an industry view (Ken Bradley)

• Drug discovery starts and ends with the patient.
• Target product profiles (TPPs) guide R&D.
• Target candidate profiles (TCPs) provide guidance and enable Go/NoGo decision making for preclinical programs.
• Examples will be provided to showcase decision making in preclinical research.

Presentation 2: Progression criteria and Go/NoGo decisions in antibacterial drug discovery – an academic view (Diarmaid Hughes)

• The academic research environment as it relates to antibiotic discovery.
• Serendipity versus planning in academic antibiotic discovery.
• The importance of projects like ENABLE in guiding academic researchers along the path to a useful drug.

This live webinar including an interactive Q&A session was broadcast on 9 April 2024.

If you have questions or comments, please let us know: revive@gardp.org.